Suspected immune checkpoint inhibitor-induced pulmonary sarcoid reaction in metastatic renal cell carcinoma
Related Experiment Video
Updated: Sep 4, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Victoria Purcell1, Beatrice Preti1,2, Ricardo Fernandes1,2,3
1Schulich School of Medicine and Dentistry Western University London Ontario Canada.
Abstract:
We present the case of a 50-year-old male patient with metastatic clear cell renal cell carcinoma (mRCC) who developed a diffuse pulmonary opacification and lymphadenopathy during nivolumab maintenance therapy. This was diagnosed as presumed sarcoid granulomatous inflammatory reaction secondary to immunotherapy, which resolved with holding off therapy and the nivolumab was resumed.
Insights
A patient with metastatic clear cell renal cell carcinoma (mRCC) experienced lung opacification and lymphadenopathy during nivolumab therapy. This immune-related adverse event, presumed sarcoidosis, resolved after treatment interruption, allowing nivolumab to be safely resumed.
Area of Science:
- Oncology
- Immunology
- Pulmonology
Background:
- Metastatic clear cell renal cell carcinoma (mRCC) is a complex malignancy.
- Immunotherapy, such as nivolumab, has revolutionized cancer treatment.
- Immune-related adverse events (irAEs) are potential complications of immunotherapy.
